Novavax WKN: A2PKMZ ISIN: US6700024010 Kürzel: NVAX Forum: Aktien Thema: Hauptdiskussion

Mal gespannt wie lange FDA und EU benötigen um eine Entscheidung zu treffen bezüglich des Antrags..

Veteran. Oh man🤦‍♂️ Vollkommen unrealistisch diese Prognose

Komisch, vor 11 Tagen 22:24 Uhr hast du noch 30-40 € zum Jahresende und Potenzial für 100 € vorausgesagt. Dann bist du ausgestiegen und nun glaubst du an das Gegenteil. Ziemlich unglaubwürdig dein Gebaren. Wenn du nicht mehr dabei bist, dann kannst du deinen 2-Wochen-Account auch gerne löschen, wäre endlich mal eine richtige Entscheidung deinerseits.

Dat geht unter 10🤪 die nächsten Wochen ☝️🧐

Highway to Hell ☝️🤪

Highway to Hell

Tenbagger = Peinlichkeiten hoch zehn 😂

So kinnas. Noch einmal schön aufgestockt. Jetzt darf es episch werden 🚀

Unglaublich 😂

Wo isser 🤡...da isser 🎪

GAITHERSBURG, Md., June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from EMA and the World Health Organization to target the JN.1 lineage this fall.1,2 "Novavax is working closely with European markets seeking to offer a protein-based alternative to mRNA this fall for COVID-19 vaccination," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our updated COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3." Nonclinical data have demonstrated that Novavax's JN.1 COVID-19 vaccine induces broad neutralization responses to JN.1 lineage viruses, including those containing the F456L and R346T mutations, and to "FLiRT" and "FLuQE" variants.2-4 Novavax's vaccine also produces conserved polyfunctional, Th1-biased CD4+ T cell responses to a range of JN.1 lineage variants.2 Novavax's JN.1 COVID-19 vaccine targets the "parent strain" of KP.2 and KP.3.2 Novavax intends to have its vaccine in unit-dose vials available for distribution in the European Union for immediate release post-approval. Novavax has also filed with the U.S. Food and Drug Administration (FDA) and is working with other regulatory authorities globally on authorization or approval of its JN.1 COVID-19 vaccine. https://finance.yahoo.com/news/novavax-submits-application-european-medicines-131800977.html?_fsig=tHwOH8zgxBYUdZB23gxRug--%7EA

Klasse, der Anstieg hat ja mal wieder keine Stunde gehalten 🙄

https://youtu.be/h-zQdhzYtO0?si=nSZ0jObsNqiauCEj

Peinlicher geht's nicht. By the way was machen deine Cavendish Anteile 🤭🤭🤭???

Langweiler

Und gleich igno de Vita💪💪